Literature DB >> 8872499

Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency.

W Pruzanski1, G Sussman, W Dorian, T Van, D Ibanez, D Redelmeier.   

Abstract

The objective was to assess clinical efficacy of 3 dosages of intravenous gammaglobulins to prevent infectious episodes in adult common variable immunodeficiency. We designed a randomized, double blind, dose-assessing study. The setting was at University Hospital, Out-patient Clinic. Our patients were twenty-one adult patients with common variable immunodeficiency. The measurements were comparative study of the number and severity of infections using 3 various dosages of intravenous gammaglobulins, each given monthly for M least 6 months. Results indicated four hundred and eighty-four infectious episodes occurred while giving 305 infusions of IVIG 200 mg/kg; 205 infectious episodes while giving 170 infusions of 400 mg/kg and 436 infectious episodes while giving 247 infusions of 600 mg/kg. The morbidity scores (infection/infusion) were 1.59, 1.21 and 1.77 respectively (p - N/S). There was no significant difference in the severity of infections on the above 3 dosages, and no difference in the duration of infection-free intervals. The conclusions resulted in no significant differences in morbidity in adult patients with common variable immunodeficiency treated in cross-over pattern with IVIG 200 mg/kg, 400 mg/kg and 600 mg/kg. Thus, high dosages of IVIG are not conferring better protection against infections in such patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872499     DOI: 10.1007/bf01486738

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  18 in total

Review 1.  Treatment of autoimmune diseases with intravenous gammaglobulin.

Authors:  E W Gelfand
Journal:  Semin Hematol       Date:  1992-07       Impact factor: 3.851

Review 2.  Can intravenous immunoglobulin treatment regulate autoimmune responses?

Authors:  S V Kaveri; G Dietrich; M D Kazatchkine
Journal:  Semin Hematol       Date:  1992-07       Impact factor: 3.851

Review 3.  Manipulating the immune system with immune globulin.

Authors:  J M Dwyer
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

Review 4.  Clinical uses of intravenous immunoglobulins.

Authors:  S A Berkman; M L Lee; R P Gale
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

Review 5.  Observations on the mode of action of normal immunoglobulin at high doses.

Authors:  A Sundblad; M A Marcos; E Malanchere; A Castro; M Haury; F Huetz; A Nobrega; A Freitas; A Coutinho
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

Review 6.  Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy.

Authors:  Y Abe; A Horiuchi; M Miyake; S Kimura
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

7.  Safety and efficacy of a monomeric, functionally intact intravenous IgG preparation in patients with primary immunodeficiency syndromes.

Authors:  M M Eibl; L Cairns; F S Rosen
Journal:  Clin Immunol Immunopathol       Date:  1984-04

8.  Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states.

Authors:  A Montanaro; B Pirofsky
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

9.  The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.

Authors:  S Mankarious; M Lee; S Fischer; K H Pyun; H D Ochs; V A Oxelius; R J Wedgwood
Journal:  J Lab Clin Med       Date:  1988-11

Review 10.  Intravenous immunoglobulin: a review.

Authors:  M M Eibl; R J Wedgwood
Journal:  Immunodefic Rev       Date:  1989
View more
  8 in total

Review 1.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 2.  Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity.

Authors:  Luanna Yang; Eveline Y Wu; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

Review 3.  An update on the use of immunoglobulin for the treatment of immunodeficiency disorders.

Authors:  Stephanie Albin; Charlotte Cunningham-Rundles
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

4.  Memory B cells in common variable immunodeficiency: clinical associations and sex differences.

Authors:  Silvia Sánchez-Ramón; Lin Radigan; Joyce E Yu; Susan Bard; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2008-07-11       Impact factor: 3.969

5.  The spectrum of disease manifestations in patients with common variable immunodeficiency disorders and partial antibody deficiency in a university hospital.

Authors:  L J Maarschalk-Ellerbroek; A I M Hoepelman; J M van Montfrans; P M Ellerbroek
Journal:  J Clin Immunol       Date:  2012-04-13       Impact factor: 8.317

Review 6.  Common variable immunodeficiency.

Authors:  W Strober; K Chua
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 10.817

7.  Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency.

Authors:  Elie Haddad; Melvin Berger; Edward C Y Wang; Christopher A Jones; Martin Bexon; Jeffrey S Baggish
Journal:  J Clin Immunol       Date:  2011-12-24       Impact factor: 8.317

8.  Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.

Authors:  Hans D Ochs; Sudhir Gupta; Peter Kiessling; Uwe Nicolay; Melvin Berger
Journal:  J Clin Immunol       Date:  2006-05       Impact factor: 8.542

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.